FineHeart, a clinical-stage MedTech company developing innovative medical devices for heart failure, has achieved a major milestone in its ...

All patients who have had a heart attack are typically treated using beta blockers. According to a recent study, this drug is unlikely to be needed for those heart patients who have a normal pumping ...

Pennington Biomedical Research Center researchers at the Metamor Institute, along with colleagues from Our Lady of the Lake and LSU Health-New Orleans, have recently determined that metabolic surgery ...

Risk for heart failure events is decreased and health status is improved in patients with HFmrEF and HFpEF receiving finerenone.

Congestive heart failure is a disease state distinguished by the regular presence of both renal and hepatic abnormalities in drug handling. One such abnormality involves flaws in the process of ...

Although finerenone has kidney protective effects in patients with chronic kidney disease and type 2 diabetes, it does not appear to slow kidney function decline in patients with heart failure with ...

Experimental Drug Engineered to Prevent Heart Failure After Heart Attacks Oct. 24, 2024 — An experimental therapeutic monoclonal antibody therapy could become the first to directly enhance ...

The costs for 806 patients with overweight or obesity and heart failure were analyzed in one study. For those patients, the average total medical costs dropped from $29,654 before treatment began to ...

in patients with chronic heart failure (CHF) and/or refractory angina with respect to 'real-life' drug side effects and toxicity, therapeutic drug level monitoring, 5 year mortality outcomes and ...

Have no fear—affinity diagrams are here to save you from getting overwhelmed by the sheer volume of data you’ve gathered. They’ll help you navigate through and organize your data in an incredibly ...

Disclaimer: The information provided here is latest and updated as available from India Post, but the users are advised to verify information with the respective Postal Office before using the ...

The ENCORE-LF study of an-caspase inhibitor emricasan in NASH cirrhosis showed that the drug was unable to meet ... advance to cirrhosis and liver failure. It is expected to become the leading ...